ZyVersa Therapeutics Inc. (ZVSA)
1.50
0.17 (12.78%)
At close: Jan 14, 2025, 3:59 PM
1.45
-3.33%
Pre-market Jan 15, 2025, 04:19 AM EST
undefined% (undefined)
| Bid | 1.44 |
| Market Cap | 3.76M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 491.97 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 1.68 |
| Volume | 704,135 |
| Avg. Volume (20D) | 1,982,714 |
| Open | 1.31 |
| Previous Close | 1.33 |
| Day's Range | 1.31 - 1.60 |
| 52-Week Range | 0.98 - 25.00 |
| Beta | undefined |
About ZVSA
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, In...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ZVSA
Website https://www.zyversa.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ZVSA stock is "Strong Buy." The 12-month stock price forecast is $240, which is an increase of 15900.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
+39.56%
ZyVersa Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
8 months ago ·
Source
+15.63%
ZyVersa Therapeutics shares are trading higher after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.
